🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

💪 We have now randomized patient no. 10 - great work team Martin Frydland, MD, PhD pernillepalm @joakimkunkel Sarah Holle Christian Hassager !!!

Very happy to attend the meeting in Acute Cardiac Care Dansk Cardiologisk Selskab (DCS) - chairing an exciting session on acute heart failure with cardiac ICU pro/con, treatment of acute heart failure, DOBERMANN-trial DOBERMANN RCT and ECMO-treatment

Patient no. 20 randomized last night 💪 Great job team! RigsHeart 🫀🚨 CRITICAL CARDIAC CARE RESEARCH GROUP Joakim Bo Kunkel Helle Søholm Christian Hassager

Yesterday, patient no. 40 was included in the #dobermann trial. We are thrilled with our current inclusion rate. Inclusion is due to the highly capable staff in the cath. lab. at RigsHeart 🫀🚨 doing a tremendous work screening all our #STEMI patients. Thank you!

We are all very excited 🤩 as we have reached a mile stone in our study - HALF WAY! Patient no. 50 have just been randomized 💪 A great thanks to everyone involved 🙏

So proud of 10 inclusions in just one month in the DOBERMANN RCT (estimated 2 per month) - only 40 to go 💪 Great team work Joakim Bo Kunkel Sarah Holle Martin Frydland, MD, PhD 🫀RigsHeart 🫀🚨 CRITICAL CARDIAC CARE RESEARCH GROUP

With an impressive inclusion rate - the team behind the DOBERMANN RCT is now reaching their goal faster than ever🏁 We can’t wait🙌 CRITICAL CARDIAC CARE RESEARCH GROUP

We have enrolled 10 patients in just one month, and reached another milestone faster than expected. 60 out of 100 patients randomized 💪 Great teamwork Sarah Holle Joakim Bo Kunkel Martin Frydland, MD, PhD Helle Søholm at RigsHeart 🫀🚨 CRITICAL CARDIAC CARE RESEARCH GROUP

#thread 1/4 DOBERMANN RCT 🧬🏥 Inflammation and neurohormonal activation have prognostic roles in AMI. The DOBERMANN RCT Trial 🐕 explores Dobutamine & Tocilizumab's potential in managing complex responses in AMI-patients with high risk of cardiogenic shock development!

#thread 2/4: DOBERMANN RCT Conducted at Copenhagen University Hospital Rigshospitalet 🇩🇰, this double-blinded, randomized, placebo-controlled trial includes AMI-patients with high-risk of cardiogenic shock development admitted for acute coronary angiography 24/7/365.

The effects of continuous IV Dobutamine and/or a single IV Tocilizumab dose post-PCI are investigated 🏥💊. Key inclusion criteria: AMI, PCI, symptom onset < 24h, ORBI score ≥10, age ≥18. Joakim Bo Kunkel

Interesting program and excellent networking opportunity - humble to be part of the #3CT 2024 meeting presenting the DOBERMANN RCT 🇩🇰🇺🇸

🔥 We are so excited (!) and thrilled to be able to share the results of the The PULSE-MI trial at an exciting #LateBreakingScience session at #ESC2024 in London this August! 🫀 RigsHeart 🫀🚨

Congratulations to all TAP-IT investigators and especially Signe Glargaard and Jens Jakob Thune for presenting the main results of the trial at the #ESCCongress2024